What semaglutide does to daily life in MASH

A paper published in JHEP Reports on 11 August 2026 reads the ESSENCE semaglutide trial from an angle the headlines skipped. Instead of liver biopsies, it asks how people with MASH actually felt during treatment, and converts their answers into a single number called health utility^[1]. The result is modest but real: after 72 weeks, patients on once-weekly semaglutide 2.4 mg reported better quality of life than patients on placebo, by a margin the authors pitch directly at pricing and reimbursement decisions^[1]. Our semaglutide page tracks the wider evidence base. This piece explains what that new number is and why it exists.

A quick orientation, then we leave the biopsy story alone

MASH stands for metabolic dysfunction-associated steatohepatitis, the inflamed form of fatty liver disease, where fat in the liver sits alongside cell injury that can slowly build scar tissue. Pathologists grade that scarring from F0, meaning none, up to F4, meaning cirrhosis. The US prescribing information for Wegovy lists the treatment of noncirrhotic MASH with moderate to advanced fibrosis, consistent with stages F2 to F3, in adults, approved under the accelerated approval pathway^[2]. The trial behind that indication is ESSENCE, a phase 3 study that randomised 1,197 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis to semaglutide 2.4 mg once weekly or placebo, reporting its first 800 patients at week 72^[3]. We covered the biopsy results and the approval itself separately; everything below is only about the quality of life analysis.

What health utility means in plain English

Health economists need a way to compare treatments for very different diseases on one scale. Health utility is that scale: a number, usually between 0 and 1, where 1 is full health and 0 is a state valued the same as being dead. The EQ-5D is the most widely used instrument for producing it. Patients rate five dimensions of daily life (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), and each combination of answers converts to a utility value using a tariff, a set of weights derived from surveys of how the general public values those health states. This analysis used the UK tariff^[1].

Multiply a utility score by the time someone spends in that health state and you get quality-adjusted life years, or QALYs. QALYs are the unit that payers and health technology assessment bodies use when they weigh a drug's price against the amount of health it buys. That is the entire reason a trial like ESSENCE bothers to collect quality of life data, and the authors say so plainly: their utility estimates are meant to feed cost-effectiveness evaluations and health technology assessments^[1].

What the analysis found

This was an exploratory analysis of the week 72 data from part 1 of ESSENCE, covering the same 800 participants: 534 on semaglutide and 266 on placebo, mean age 56 years, 57.1% female, mean body mass index 34.6, with 55.9% living with type 2 diabetes^[1]. The trial had collected a general health questionnaire called the Short Form-36, or SF-36, and the authors converted those answers into EQ-5D utility scores using a published mapping algorithm^[1]. The authors are Novo Nordisk employees, and Novo Nordisk funded the parent trial^[3].

At baseline, mapped utility sat at roughly 0.78 in both groups, already well below the 1.0 of full health^[1]. At week 72, the semaglutide group improved relative to placebo by an estimated 0.03 utility points (95% confidence interval 0.01 to 0.06, nominal P value 0.0015), with a consistent direction of effect across fibrosis stages^[1]. One texture note from the primary publication: mean changes in bodily pain scores did not differ significantly between the groups, so whatever drove the utility gain ran through the other dimensions of daily life^[3].

Why three hundredths of a point is not nothing

A 0.03 difference sounds tiny next to a 0 to 1 scale. Cost-effectiveness arithmetic works in exactly these increments. If a treatment holds a small utility gain for years across a large patient population, the QALYs accumulate, and reimbursement agencies compare that accumulated benefit against the drug's price^[1]. The label context raises the stakes. Wegovy's MASH indication is an accelerated approval, and the prescribing information states that continued approval may be contingent on confirmation of clinical benefit in a confirmatory trial^[2]. While that confirmation is pending, every quantified patient benefit carries weight in coverage talks, and quality of life is one of the few outcomes in this trial measured from the patient's side of the microscope.

The caveats the authors flag themselves

First, nobody in the trial filled in an actual EQ-5D form. The utilities were mapped from SF-36 scores using an algorithm published by Rowen and colleagues in 2009^[1]. Mapping is an accepted technique, but Rowen's own validation work found that mapped scores overpredict utility for people in worse health states, meaning the gain here could be sized differently if EQ-5D had been measured directly^[4]. Second, the UK tariff means the exact values may not transfer to other countries, a caution the authors state outright^[1]. Third, this was an exploratory analysis carrying a nominal P value, not a pre-specified primary endpoint. The trial's primary endpoints were biopsy findings, and the long-term question of whether semaglutide prevents cirrhosis remains open, as covered on our semaglutide evidence page.

Where this lands

For someone with MASH, this paper says that over 72 weeks, semaglutide 2.4 mg improved day-to-day quality of life by a small but statistically measurable amount compared with placebo, alongside the biopsy improvements reported earlier^[1]. It does not show people felt dramatically better, and the mapping method adds uncertainty to the exact size of the gain. For anyone watching access and coverage, the utility figure is the number to track, because it is the input cost-effectiveness models need^[1]. The safety profile, the dosing schedule used in trials, and country-by-country regulatory status sit on the main semaglutide page.

This article is educational and journalistic. It is not medical advice, and PeptideMethods does not advise on starting, stopping, dosing or obtaining any medicine. Decisions about liver disease treatment belong with a healthcare provider who knows your history and can read your test results.